OncoMatch/Clinical Trials/NCT05467748
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Is NCT05467748 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Tulmimetostat for non small cell lung cancer.
Treatment: Tulmimetostat — This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. Patients will be enrolled at multiple Veterans Affairs Medical Centers.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: EGFR altered
EGFR or ALK altered patients [excluded]
Excluded: ALK altered
EGFR or ALK altered patients [excluded]
Disease stage
Metastatic disease required
advanced non-small cell lung cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy — monotherapy or in combination
Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies
Cannot have received: EZH2 inhibitor (tulmimetostat)
Prior exposure to tulmimetostat or other EZH2 inhibitors
Cannot have received: immunotherapy
Immunotherapy naïve patients [excluded]
Lab requirements
Blood counts
Absolute neutrophil counts (ANC) 1500/mm3; Platelet count 100,000/mm3; Hemoglobin 9 g/dL without need for hematopoietic growth factor or transfusion support; Prothrombin time (PT) 1.5 x ULN and INR 1.3; Partial thromboplastin time (PTT) 1.5 ULN
Kidney function
Serum creatinine 1.5 x ULN, or 24-hour creatinine clearance 30 cc/min
Liver function
Serum bilirubin 1.5 ×ULN OR direct bilirubin ULN for participants with total bilirubin levels >1.5 × ULN; AST 2.5 ULN or 5XULN for subjects with liver metastases; ALT 2.5 ULN or 5XULN for subjects with liver metastases; Alkaline phosphatase 2.5 X ULN of liver fraction if 2.5 X ULN; Serum albumin 2.5g/dL
Adequate organ function. (must be within 10 days prior to start of study intervention)...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- VA Long Beach Healthcare System, Long Beach, CA · Long Beach, California
- VA Northern California Health Care System, Mather, CA · Sacramento, California
- VA San Diego Healthcare System, San Diego, CA · San Diego, California
- VA Ann Arbor Healthcare System, Ann Arbor, MI · Ann Arbor, Michigan
- Michael E. DeBakey VA Medical Center, Houston, TX · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05467748 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior EZH2 inhibitor, immunotherapy disqualifies patients from enrollment.
Are patients with EGFR alterations eligible?
No. EGFR altered is an exclusion criterion.
Are patients with ALK alterations eligible?
No. ALK altered is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages